Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Has at least a 1-year history of migraine with or without aura~* Age of the patient at the time of migraine onset \< 50 years~* History of 4 to 14 migraine days (migraine/probable migraine headache days) per month on average in the 3 months prior to Visit 1 in the Investigator's judgment~* Demonstrated compliance with e-diary~Exclusion Criteria:~* Has a history of migraine accompanied by diplopia or decreased level of consciousness and retinal migraine~* Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy~* Difficulty distinguishing migraine headache from other headaches~* Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer~* Has a history of gastric or small intestinal surgery, or has a disease that causes malabsorption~* Has a history of hepatitis within previous 6 months~* Usage of opioids or barbiturates \> 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (eg, aspirin, non-steroidal anti-inflammatory drugs \[NSAIDs\], acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1~* Pregnant or nursing females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
- Atogepant 10 mg QD (Type: EXPERIMENTAL): Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
- Atogepant 30 mg QD (Type: EXPERIMENTAL): Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
- Atogepant 30 mg BID (Type: EXPERIMENTAL): Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
- Atogepant 60 mg QD (Type: EXPERIMENTAL): Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
- Atogepant 60 mg BID (Type: EXPERIMENTAL): Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).